Highlights

• Biotech Growth Trust raises net asset value per share by 14.8% to 1,623.8p over six months.

• The share price climbs 22.9% to 1,548.0p as the discount narrows from 10.9% to 4.7%.

• The trust repurchases 1,114,074 of its own shares for £15.7m, adding 0.5% to net asset value.

• Gearing falls to nil, leaving the trust with net cash of 5.2% at the end of September.

Zero borrowing, a single-digit discount and five holdings subject to announced takeovers: that is the shape of the portfolio Biotech Growth Trust (LSE:BIOG) describes in its unaudited half-year report for the six months to 30 September 2026. The update covers returns, the trust's own share buybacks, the stocks that moved the needle and a Balance Sheet that ended the period holding cash rather than debt.

Net asset value, share price and benchmark

Net asset value per share rose 14.8%, from 1,414.6p to 1,623.8p. The share price increased 22.9%, from 1,260.0p to 1,548.0p. The Nasdaq Biotechnology Index, the trust's benchmark, rose 21.6% over the period.

Because the share price moved further than the net asset value, the discount at which the shares trade narrowed from 10.9% to 4.7%. For a closed-end fund, that gap between the Market Price and the underlying asset value is one of the main measures shareholders track.

Buybacks at an average 9.0% discount

During the half Biotech Growth Trust (LSE:BIOG) bought back 1,114,074 shares at an average discount of 9.0%. The repurchases cost £15.7m and represented 5.6% of the shares in issue at the start of the period.

Buying shares below asset value adds to NAV for the remaining holders, and the trust puts that contribution at 0.5%. The buyback programme ran alongside the narrowing of the discount over the six months.

What drove the portfolio

The top contributors added around 142.7p per share to performance, while detractors accounted for around 54.5p per share. Five holdings in the portfolio were the subject of announced acquisitions during the period; the announcement does not disclose their names.

A calculation based on the disclosed figures shows the gap between the contributions of the leading and lagging holdings at around 88.2p per share. Five announced acquisitions within a single half year also form a notable part of the portfolio story.

Gearing, cash and costs

Gearing at Biotech Growth Trust (LSE:BIOG) was reduced to nil over the period, and the trust ended September with net cash of 5.2%. The ongoing charges figure, which expresses the annual running costs as a proportion of the trust's assets, stood at 1.2%.

Moving from borrowed money to a net cash position changes how the portfolio is exposed to market moves, since the trust is no longer investing more than its own net assets. Alongside the Buybacks and the narrower discount, the balance sheet entering the second half is ungeared and cash-positive.

What the Discount Figures Mean

Investment trusts trade on the stock market at a price that can differ from the value of the Assets they hold. The difference is called the discount when the share price is lower than the net asset value. Biotech Growth Trust's discount narrowed from 10.9% to 4.7% because the share price rose 22.9% while the NAV per share rose 14.8%. The trust also repurchased shares at an average discount of 9.0%, and it estimates that this added 0.5% to NAV for the remaining holders.

Portfolio Drivers and the Balance Sheet

The top contributors added around 142.7p per share while detractors accounted for around 54.5p per share, which gives a net positive picture across the half. Five holdings were subject to announced acquisitions, a feature of the biotechnology sector in which larger companies often acquire smaller developers, although the announcement does not name the holdings. Alongside the NASDAQ Biotechnology index rise of 21.6%, the trust's NAV and share price increases give two comparisons for readers to consider. The ongoing charges figure of 1.2% describes the annual running costs as a share of assets. Gearing was reduced to nil and net cash was 5.2% at the end of September, so the trust is investing within its own net assets rather than using borrowed money.